201 related articles for article (PubMed ID: 21466449)
1. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation.
Alvarez-Jaimes LJ; Palmer JA
Curr Pharm Biotechnol; 2011 Oct; 12(10):1644-59. PubMed ID: 21466449
[TBL] [Abstract][Full Text] [Related]
2. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
3. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
Vandevoorde S; Lambert DM
Curr Pharm Des; 2005; 11(20):2647-68. PubMed ID: 16101463
[TBL] [Abstract][Full Text] [Related]
4. Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.
Chicca A; Arena C; Manera C
Recent Pat CNS Drug Discov; 2016; 10(2):122-141. PubMed ID: 27630088
[TBL] [Abstract][Full Text] [Related]
5. Fatty pain cures.
Imming P
Chem Biol; 2007 Dec; 14(12):1311-2. PubMed ID: 18096498
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
Saario SM; Laitinen JT
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):287-93. PubMed ID: 17910610
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis.
Feledziak M; Lambert DM; Marchand-Brynaert J; Muccioli GG
Recent Pat CNS Drug Discov; 2012 Apr; 7(1):49-70. PubMed ID: 22280341
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
9. Novel natural and synthetic ligands of the endocannabinoid system.
Hanus LO; Mechoulam R
Curr Med Chem; 2010; 17(14):1341-59. PubMed ID: 20166928
[TBL] [Abstract][Full Text] [Related]
10. A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling.
Labar G; Wouters J; Lambert DM
Curr Med Chem; 2010; 17(24):2588-607. PubMed ID: 20491633
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons.
Marrs WR; Horne EA; Ortega-Gutierrez S; Cisneros JA; Xu C; Lin YH; Muccioli GG; Lopez-Rodriguez ML; Stella N
J Biol Chem; 2011 Aug; 286(33):28723-28728. PubMed ID: 21665953
[TBL] [Abstract][Full Text] [Related]
12. Chemical probes of endocannabinoid metabolism.
Blankman JL; Cravatt BF
Pharmacol Rev; 2013 Apr; 65(2):849-71. PubMed ID: 23512546
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Hwang J; Adamson C; Butler D; Janero DR; Makriyannis A; Bahr BA
Life Sci; 2010 Apr; 86(15-16):615-23. PubMed ID: 19527737
[TBL] [Abstract][Full Text] [Related]
14. New insights into endocannabinoid degradation and its therapeutic potential.
Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse.
Palmer JA; Higuera ES; Chang L; Chaplan SR
Neuroscience; 2008 Jul; 154(4):1554-61. PubMed ID: 18541380
[TBL] [Abstract][Full Text] [Related]
16. The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.
Fowler CJ
Handb Exp Pharmacol; 2015; 231():95-128. PubMed ID: 26408159
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of the endocannabinoid system in the sleep-wake cycle modulation.
Murillo-Rodriguez E; Poot-Ake A; Arias-Carrion O; Pacheco-Pantoja E; Fuente-Ortegon Ade L; Arankowsky-Sandoval G
Cent Nerv Syst Agents Med Chem; 2011 Sep; 11(3):189-96. PubMed ID: 21919868
[TBL] [Abstract][Full Text] [Related]
18. Modulators of endocannabinoid enzymic hydrolysis and membrane transport.
Ho WS; Hillard CJ
Handb Exp Pharmacol; 2005; (168):187-207. PubMed ID: 16596775
[TBL] [Abstract][Full Text] [Related]
19. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.
Pertwee RG
Proc Nutr Soc; 2014 Feb; 73(1):96-105. PubMed ID: 24135210
[TBL] [Abstract][Full Text] [Related]
20. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
Vandevoorde S
Curr Top Med Chem; 2008; 8(3):247-67. PubMed ID: 18289091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
